论文部分内容阅读
目的评价坦索罗辛联合非那雄胺治疗老年前列腺增生症患者的临床疗效及安全性。方法 76例老年前列腺增生症患者按照不平衡指数最小的分配原则分为单一组和联合组,每组38例,单一组给予非那雄胺治疗,5 mg/次,1次/d,于每晚睡前温水口服。联合组给予坦索罗辛联合非那雄胺治疗,坦索罗辛0.2mg/次,1次/d,于每晚睡前温水口服,非那雄胺服用方法同单一组。两组疗程均为3个月。采用国际前列腺症状评分(IPSS)标准评价两组临床疗效,治疗前后采用阿森斯失眠量表(AIS)对两组治疗前后睡眠状态进行评价,采用生活质量评分标准(QOL)评价生活质量,并观察不良反应发生率。结果单一组与联合组临床疗效比较,P<0.05;联合组治疗后AIS评分低于单一组,QOL评分高于单一组,差异有统计学意义(P<0.05);单一组不良反应发生率为7.89%(3/38),联合组不良反应发生率为10.53%(4/38),χ2=0.000,P>0.05。结论坦索罗辛联合非那雄胺治疗老年前列腺增生症患者疗效好、安全,并能改善生活质量。
Objective To evaluate the clinical efficacy and safety of tamsulosin plus finasteride in the treatment of elderly patients with benign prostatic hyperplasia. Methods A total of 76 elderly BPH patients were divided into single group and combined group according to the principle of least unbalanced distribution. Each group had 38 patients treated with finasteride, 5 mg once daily, Warm before going to bed orally. The combination group was given tamsulosin combined with finasteride treatment, tamsulosin 0.2mg / time, 1 time / d, warm water before going to bed every night oral administration of finasteride with a single group. Two groups of treatment are 3 months. The clinical efficacy was evaluated by International Prostate Symptom Score (IPSS). Before and after treatment, the Aches Insomnia Scale (AIS) was used to evaluate the sleep status before and after treatment. Quality of life was assessed by Quality of Life Scale (QOL) Adverse reaction rate. Results The clinical curative effect of the single group and the combined group was significant (P <0.05). The AIS score of the combined group was lower than that of the single group, and the QOL score was higher than that of the single group (P <0.05). The incidence of adverse reactions in the single group was 7.89% (3/38). The incidence of adverse reactions in the combination group was 10.53% (4/38), χ2 = 0.000, P> 0.05. Conclusion Tamsulosin combined with finasteride treatment of elderly patients with benign prostatic hyperplasia efficacy, safety, and can improve the quality of life.